Ozempic vs Wegovy vs Mounjaro vs Zepbound (2026): GLP-1 Weight Loss & Diabetes Drugs Compared

A 2026 evidence-based comparison of the four leading GLP-1 medications — Ozempic, Wegovy, Mounjaro, and Zepbound — covering efficacy, dosing, side effects, costs, insurance coverage, and how to choose between them.

By Symptom Advisory Editorial Team — last reviewed August 18, 2026 — 10 min read

Ozempic vs Wegovy vs Mounjaro vs Zepbound (2026): GLP-1 Weight Loss & Diabetes Drugs Compared

Key Takeaways

  • Tirzepatide (Mounjaro/Zepbound) showed ~20% average weight loss vs ~14% for semaglutide (Ozempic/Wegovy) in head-to-head trials.
  • Ozempic and Mounjaro are FDA-approved for type 2 diabetes; Wegovy and Zepbound are approved for chronic weight management.
  • US list prices range $998–$1,349/month before insurance; coverage varies widely and Medicare excludes obesity-only indications.
  • Both classes carry similar GI side effects (nausea, diarrhea) and rare risks including pancreatitis and gallbladder disease.
  • Stopping the medication typically leads to substantial weight regain — these are chronic, not short-term, treatments.

Why GLP-1 Drugs Changed Everything

In just under five years, GLP-1 receptor agonists have gone from a niche diabetes therapy to the most-discussed class of prescription medications in the United States. As of early 2026, roughly 1 in 8 American adults has tried a GLP-1 drug at some point, according to KFF Health Tracking Polls. The market is now dominated by four products from two manufacturers: Ozempic and Wegovy (both semaglutide, Novo Nordisk) and Mounjaro and Zepbound (both tirzepatide, Eli Lilly).

The drugs work by mimicking gut hormones (GLP-1 alone, or GLP-1 plus GIP in the case of tirzepatide) that slow gastric emptying, blunt appetite, and improve insulin sensitivity. The clinical results are striking — but so are the costs, the side effects, and the gray area around insurance coverage.

This guide compares the four medications head-to-head on the things that actually matter when you and your clinician are choosing between them.

The Two Active Ingredients, Four Brand Names

It is worth understanding upfront that there are only two molecules involved:

  • Semaglutide — sold as Ozempic (FDA-approved 2017 for type 2 diabetes) and Wegovy (FDA-approved 2021 for chronic weight management).
  • Tirzepatide — sold as Mounjaro (FDA-approved 2022 for type 2 diabetes) and Zepbound (FDA-approved 2023 for chronic weight management, and 2024 for obstructive sleep apnea in adults with obesity).

The diabetes-labeled versions (Ozempic, Mounjaro) and the obesity-labeled versions (Wegovy, Zepbound) contain the same active ingredient at the same or similar maximum doses. The differences are in approved indication, maximum dose, packaging, and — critically — insurance handling.

Head-to-Head Efficacy

Weight loss data from the pivotal trials:

  • Semaglutide 2.4 mg (Wegovy) — STEP 1 trial: average 14.9% body weight loss at 68 weeks vs 2.4% on placebo (NEJM, 2021).
  • Tirzepatide 15 mg (Zepbound) — SURMOUNT-1 trial: average 20.9% body weight loss at 72 weeks vs 3.1% on placebo (NEJM, 2022).
  • Head-to-head SURMOUNT-5 (2024): tirzepatide produced 20.2% weight loss vs semaglutide's 13.7% at 72 weeks — a roughly 47% greater reduction.

For type 2 diabetes (HbA1c reduction), tirzepatide also outperformed semaglutide head-to-head in SURPASS-2, with HbA1c drops of 2.0–2.3% on tirzepatide vs 1.86% on semaglutide.

In plain terms: tirzepatide is, on average, more effective for both weight loss and glycemic control, though individual response varies widely.

Side Effects: Mostly GI, Mostly Manageable

Both drug classes share the same dominant side effect profile:

  • Nausea (most common, typically peaks 2–3 days after a dose increase)
  • Diarrhea or constipation
  • Vomiting
  • Reduced appetite (sometimes excessive)
  • Fatigue, especially during dose escalation

Serious but rare risks include acute pancreatitis, gallbladder disease, bowel obstruction (ileus), and a boxed warning for thyroid C-cell tumors based on rodent data — though no causal link has been established in humans.

The FDA added warnings in 2023–2024 about pulmonary aspiration during anesthesia because of delayed gastric emptying; most anesthesiologists now ask patients to hold their dose for at least one week before surgery.

Tirzepatide tends to produce slightly more GI side effects at equivalent dose-escalation steps, but tolerability profiles are broadly similar.

What They Cost in 2026

US list prices, before insurance or manufacturer coupons:

  • Ozempic: ~$998 per month
  • Wegovy: ~$1,349 per month
  • Mounjaro: ~$1,069 per month
  • Zepbound: ~$1,059 per month (vial program from Lilly Direct: $349–$499/month for self-pay)

Insurance coverage is the central problem. Most commercial insurers cover the diabetes-labeled drugs (Ozempic, Mounjaro) for patients with type 2 diabetes, but roughly half of commercial plans either exclude weight-loss drugs entirely or require extensive prior authorization. Medicare Part D is statutorily prohibited from covering anti-obesity medications, though Wegovy gained coverage in 2024 for patients with established cardiovascular disease following the SELECT trial results, and Zepbound gained coverage in 2025 for moderate-to-severe obstructive sleep apnea.

The manufacturer savings programs (NovoCare for Wegovy, Lilly's Zepbound Savings Card) can reduce out-of-pocket costs to $25/month with commercial insurance or as low as $349–$499 for cash-pay vials, but these programs change frequently and have eligibility caps.

Compounded GLP-1s: Buyer Beware

During the FDA-declared shortages of 2022–2024, compounding pharmacies legally produced semaglutide and tirzepatide at lower prices. Both shortages were declared resolved in 2024, and the FDA has since taken enforcement action against large-scale compounders. As of 2026:

  • Compounded tirzepatide is no longer permitted by traditional compounders (only 503B outsourcing facilities under narrow circumstances).
  • Compounded semaglutide remains in a legal gray zone but is increasingly restricted.
  • The FDA has warned that some compounded products tested contained incorrect dosages, impurities, or even unrelated salt forms (e.g., semaglutide sodium) that have never been clinically studied.

If cost is the barrier, the Lilly Direct self-pay vial program for Zepbound and the NovoCare cash-pay program for Wegovy are safer routes than compounded versions.

Beyond Weight: Other Approved and Emerging Uses

The therapeutic story is broadening rapidly:

  • Cardiovascular protection: SELECT trial (2023) showed semaglutide reduced major adverse cardiovascular events by 20% in adults with obesity and established CV disease — leading to a new Wegovy indication.
  • Obstructive sleep apnea: SURMOUNT-OSA (2024) led to a Zepbound indication.
  • Chronic kidney disease: FLOW trial showed semaglutide slowed CKD progression in type 2 diabetes.
  • MASH (fatty liver disease): Phase 3 trials ongoing for both molecules; positive results expected through 2026.
  • Alcohol and substance use disorders: Multiple Phase 2 trials underway; early signals are intriguing but inconclusive.

How to Choose Between Them

The choice typically comes down to:

  1. Indication — If you have type 2 diabetes, Ozempic or Mounjaro will almost always be covered; if your goal is weight loss without diabetes, you need Wegovy or Zepbound.
  2. Effectiveness target — For maximum weight loss, tirzepatide (Zepbound) has the strongest data.
  3. Tolerability — Semaglutide is sometimes better tolerated at maximum dose; only a trial will tell.
  4. Cost and access — Check your formulary first; the answer may make the decision for you.
  5. Comorbidities — Established CVD favors Wegovy; severe sleep apnea favors Zepbound; CKD favors semaglutide.

This is a conversation to have with a clinician who can review your specific medical history, current medications, and insurance situation.

What Happens If You Stop

Both classes are chronic medications, not short-term interventions. The STEP-4 extension trial showed patients who discontinued semaglutide regained about two-thirds of lost weight within 1 year. SURMOUNT-4 showed similar weight regain after tirzepatide discontinuation. The biology of obesity does not "reset" — appetite and metabolic adaptations return when the drug is withdrawn.

This is one reason the long-term costs matter so much: most patients who benefit from these drugs will likely need them indefinitely, much like blood pressure or cholesterol medications.

Bottom Line

For pure weight-loss potency, tirzepatide (Mounjaro/Zepbound) currently leads the head-to-head data. For broader evidence of cardiovascular benefit and a longer safety record, semaglutide (Ozempic/Wegovy) has the deepest track record. For most patients, the actual choice will be determined by what your insurance covers and what your clinician thinks fits your specific health profile. The science is moving fast — expect new comparative data, new indications, and likely new oral GLP-1 options through 2026 and 2027.

Practical Checklist

  • Confirm which indication applies to you (diabetes vs weight management) — this drives insurance coverage.
  • Check your insurance formulary or call member services before requesting a specific brand.
  • Ask your clinician about manufacturer savings programs (NovoCare, Lilly Direct).
  • Plan for gradual dose escalation over 16–20 weeks to minimize GI side effects.
  • Hold the dose 1 week before any scheduled surgery requiring anesthesia.
  • Avoid compounded GLP-1 products from non-503B sources.
  • Treat this as long-term therapy — discuss the discontinuation plan upfront.

Frequently Asked Questions

Is Ozempic the same as Wegovy?

Both contain the same active ingredient — semaglutide — made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes (max dose 2 mg weekly); Wegovy is approved for chronic weight management at a higher max dose of 2.4 mg weekly. Insurance treats them very differently.

Which is more effective for weight loss: Ozempic/Wegovy or Mounjaro/Zepbound?

In the SURMOUNT-5 head-to-head trial (2024), tirzepatide produced about 20% body weight loss vs semaglutide's 14% at 72 weeks. Tirzepatide-based drugs (Mounjaro, Zepbound) currently lead on weight-loss potency, though individual response varies.

Will my insurance cover these medications?

Most plans cover Ozempic and Mounjaro for type 2 diabetes. Coverage of Wegovy and Zepbound for obesity is inconsistent — roughly half of commercial plans cover them, often with prior authorization. Medicare Part D cannot cover anti-obesity drugs except for specific approved indications like cardiovascular disease (Wegovy) or moderate-to-severe sleep apnea (Zepbound).

What are the most common side effects?

Nausea, diarrhea, constipation, vomiting, and reduced appetite — mostly during dose escalation. These usually improve with slower titration. Rare but serious risks include pancreatitis, gallbladder disease, and bowel obstruction.

Are compounded GLP-1 medications safe?

The FDA declared the shortages of both molecules resolved in 2024, and most traditional compounding is no longer permitted. The FDA has warned that some compounded products contained incorrect dosages or unstudied salt forms. Stick with FDA-approved products via manufacturer savings programs if cost is a barrier.

Do you regain weight if you stop taking the medication?

Yes — clinical extension trials (STEP-4, SURMOUNT-4) showed patients regained roughly two-thirds of lost weight within a year of stopping. GLP-1 drugs are considered chronic therapy, similar to blood pressure medication.

Can I take a GLP-1 if I don't have diabetes or obesity?

FDA-approved indications require either type 2 diabetes, a BMI ≥30, or a BMI ≥27 with at least one weight-related comorbidity. Off-label use exists but is generally not covered by insurance and is not recommended without a clear medical rationale.

Are there oral versions of these drugs?

Yes — Rybelsus is an oral semaglutide tablet approved for type 2 diabetes (lower efficacy than injectable). Lilly's oral GLP-1 candidate orforglipron is in Phase 3 trials with results expected through 2026, and oral semaglutide is being studied at higher doses for weight loss.

Sources & References

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine link
  2. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine link
  3. Tirzepatide vs Semaglutide for the Treatment of Obesity (SURMOUNT-5) — New England Journal of Medicine link
  4. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine link
  5. Tirzepatide for the Treatment of Obstructive Sleep Apnea (SURMOUNT-OSA) — New England Journal of Medicine link
  6. FDA Updates on GLP-1 Receptor Agonists and Compounded Products — U.S. Food and Drug Administration link
  7. KFF Health Tracking Poll: Public Awareness and Use of GLP-1 Drugs — Kaiser Family Foundation link
  8. Standards of Care in Diabetes — 2025: Pharmacologic Approaches — American Diabetes Association link

Medical disclaimer

This article is health information for education only. It is not medical advice, a diagnosis or a treatment plan. In an emergency, call 911. Researched and drafted with AI-assisted tools and fact-checked by a human editor against the sources listed above. How we create our content.